Journal of Nuclear Science, Engineering and Technology (JONSAT)
In cooperation with the Iranian Nuclear Society

Production, Quality Control and Biological Evaluation of 90Y-EDTMP in Rats

Document Type : Research Paper

Authors

R Adeli
M Ghannadi Maragheh
M Shamsaei Zafarghandi
A Bahrami Samani
B Salimi
Abstract
Pain palliation of bone metastases is one of the perspectives of medical science. Among the different modalities, the use of radionuclides is a well-established approach. One of these radionuclides is Yttrium-90 (90Y) associated with chemical component EDTMP. One method for production of 90Y is neutron activation of 89Y. This radionuclide is a pure beta emitter with a high energy and appropriate half life and has been considered for medical usages in nuclear medicine. In this research 90Y has been produced by irradiation of Y­­­­­2­­O­­­3 powder and by the addition of EDTMP ligand, the 90Y-EDTMP complex has been achieved at ambient temperature. Radiochemical purity was investigated by ITLC method and radionuclidic purity by liquid scintillation counting. The radiopharmaceutical biodistributions were performed in different rat organs. 

Highlights

References:

 

  1. 1.    Aldo N .Serafani, “Therapy of metastatic bone pain,” J. Nucl. Med. 42 (6), 895- 906 (2001).

 

  1. 2.    “Criteria for palliation of bone metastases- Clinical Applications,” IAEA-TECDOC-1549 (2007).

 

  1. 3.    Yang Zhi, Jin Xiaohai, Yu Haibin, Bai Shouzhen (Institute of Atomic Energy, Beijing 102413), “Preparation of 90Y-EDTMP for bone tomor treatment,” J. Isotopes 5 (2): 72 (1992).

 

  1. 4.    Sharmile Banerjee, “177Lu-DOTMP, 153Sm-DOTMP, 175Yb-EDTMP and 186/188Re-CTMP: “Novel agent for bone pain pallation and their comparison With 153Sm-EDTMP,” Founder’s Day Special Issue (2005).

 

  1. 5.    J. Kutzer, W. Dahnert, T. Schreyer, W. Grimm, Brod Kh, M. Becher, “Treatment of pain from bone metastase with 90Y,” Nuklearmedizin 20, 229-235 (1981).

 

  1. 6.    M. Khalid, A. Mushtaq, “Preparation and in vitro stability of (n,γ) Yttrium-90 Hydroxyapatite,” Applied Radiation and Isotopes 62, 587-590 (2005).

 

  1. 7.    F. Rosch and co-workers, “Radiation doses of Yttrium-90 citrate and Yttrium-90 EDTMP as determined via analogous Yttrium-86 complexes and positron emission tomography,” Eur. J. Nucl. Med, 23:958–966 (1996).

 

  1. 8.    A.A. Keeling, A.T.M. Vaughan, R.P. Beaney, “Yttrium-90-EDTMP: A radio therapeutic agent in the treatment of leukaemies,” Br. J. Cancer 60, 74-78 (1989).

Keywords

Bone Metastases
Yttrium-90
EDTMP
Radiopharmaceutical
Biodistribution

  1. References:

     

    1. 1.    Aldo N .Serafani, “Therapy of metastatic bone pain,” J. Nucl. Med. 42 (6), 895- 906 (2001).

     

    1. 2.    “Criteria for palliation of bone metastases- Clinical Applications,” IAEA-TECDOC-1549 (2007).

     

    1. 3.    Yang Zhi, Jin Xiaohai, Yu Haibin, Bai Shouzhen (Institute of Atomic Energy, Beijing 102413), “Preparation of 90Y-EDTMP for bone tomor treatment,” J. Isotopes 5 (2): 72 (1992).

     

    1. 4.    Sharmile Banerjee, “177Lu-DOTMP, 153Sm-DOTMP, 175Yb-EDTMP and 186/188Re-CTMP: “Novel agent for bone pain pallation and their comparison With 153Sm-EDTMP,” Founder’s Day Special Issue (2005).

     

    1. 5.    J. Kutzer, W. Dahnert, T. Schreyer, W. Grimm, Brod Kh, M. Becher, “Treatment of pain from bone metastase with 90Y,” Nuklearmedizin 20, 229-235 (1981).

     

    1. 6.    M. Khalid, A. Mushtaq, “Preparation and in vitro stability of (n,γ) Yttrium-90 Hydroxyapatite,” Applied Radiation and Isotopes 62, 587-590 (2005).

     

    1. 7.    F. Rosch and co-workers, “Radiation doses of Yttrium-90 citrate and Yttrium-90 EDTMP as determined via analogous Yttrium-86 complexes and positron emission tomography,” Eur. J. Nucl. Med, 23:958–966 (1996).

     

    1. 8.    A.A. Keeling, A.T.M. Vaughan, R.P. Beaney, “Yttrium-90-EDTMP: A radio therapeutic agent in the treatment of leukaemies,” Br. J. Cancer 60, 74-78 (1989).

Home